Buy­out buzz cen­ters on a No­var­tis NASH deal for Gen­fit; Syn­thon joins the CD47 club

→ Gen­fit $GN­FT has be­come the tar­get of the lat­est round of M&A ru­mors. StreetInsid­er says that No­var­tis is close to a deal to ac­quire France’s Gen­fit, which has been work­ing on a new drug for NASH, now in Phase III.

→ You can wel­come the Dutch biotech Syn­thon to the ranks of CD47 drug de­vel­op­ers. Syn­thon has li­censed world­wide rights to San­quin’s lead an­ti­bod­ies and IP re­gard­ing the CD47-SIR­Pα path­way to de­vel­op new im­muno-on­col­o­gy treat­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.